Literature DB >> 22487943

Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice.

Leonhard Stross1, Johannes Günther, Georg Gasteiger, Theresa Asen, Stefanie Graf, Michaela Aichler, Irene Esposito, Dirk H Busch, Percy Knolle, Tim Sparwasser, Ulrike Protzer.   

Abstract

UNLABELLED: The strength of antiviral T cell responses correlates with clearance of hepatitis B virus (HBV) infection, but the immunological mechanisms mitigating or suppressing HBV-specific T cells are still poorly understood. In this study, we examined the role of CD4(+) Foxp3(+) regulatory T cells (Tregs) in a mouse model of acute HBV infection. We initiated HBV infection via an adenoviral vector transferring a 1.3-fold overlength HBV genome (AdHBV) into transgenic DEREG mice, where Tregs can be transiently but selectively depleted by injection of diphtheria toxin. The effect of Treg depletion on the outcome of HBV infection was characterized by detailed virological, immunological, and histopathological analysis. Numbers of Tregs increase in the liver rapidly after initiation of HBV replication. Initial depletion of Tregs revealed their complex regulatory function during acute infection. Tregs mitigated immunomediated liver damage by down-regulating the antiviral activity of effector T cells by limiting cytokine production and cytotoxicity, but did not influence development of HBV-specific CD8 T cells or development of memory T cells. Furthermore, Tregs controlled the recruitment of innate immune cells such as macrophages and dendritic cells to the infected liver. As a consequence, Tregs significantly delayed clearance of HBV from blood and infected hepatocytes.
CONCLUSION: Tregs limit immunomediated liver damage early after an acute infection of the liver, thereby contributing to conservation of tissue integrity and organ function at the cost of prolonging virus clearance.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22487943     DOI: 10.1002/hep.25765

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  44 in total

Review 1.  Prognostic significance of regulatory T lymphocytes in patients with hepatocellular carcinoma.

Authors:  Ai-Bin Zhang; Yi-Gang Qian; Shu-Sen Zheng
Journal:  J Zhejiang Univ Sci B       Date:  2016 Dec.       Impact factor: 3.066

2.  The transcription factor c-JUN/AP-1 promotes HBV-related liver tumorigenesis in mice.

Authors:  C Trierweiler; B Hockenjos; K Zatloukal; R Thimme; H E Blum; E F Wagner; P Hasselblatt
Journal:  Cell Death Differ       Date:  2015-10-16       Impact factor: 15.828

Review 3.  Restoring homeostasis of CD4⁺ T cells in hepatitis-B-virus-related liver fibrosis.

Authors:  Li-Sha Cheng; Yun Liu; Wei Jiang
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

Review 4.  T lymphocytes in hepatocellular carcinoma immune microenvironment: insights into human immunology and immunotherapy.

Authors:  Jin Bian; Jianzhen Lin; Junyu Long; Xu Yang; Xiaobo Yang; Xin Lu; Xinting Sang; Haitao Zhao
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

5.  The hepatitis B virus-associated tumor microenvironment in hepatocellular carcinoma.

Authors:  Pengyuan Yang; Geoffrey J Markowitz; Xiao-Fan Wang
Journal:  Natl Sci Rev       Date:  2014-07-14       Impact factor: 17.275

Review 6.  Environmental peer pressure: CD4+ T cell help in tolerance and transplantation.

Authors:  Dana Tedesco; Arash Grakoui
Journal:  Liver Transpl       Date:  2018-01       Impact factor: 5.799

7.  CD4+ Foxp3+ T cells promote aberrant immunoglobulin G production and maintain CD8+ T-cell suppression during chronic liver disease.

Authors:  Dana Tedesco; Manoj Thapa; Sanjeev Gumber; Elizabeth J Elrod; Khalidur Rahman; Chris C Ibegbu; Joseph F Magliocca; Andrew B Adams; Frank Anania; Arash Grakoui
Journal:  Hepatology       Date:  2016-12-19       Impact factor: 17.425

Review 8.  Mouse models for therapeutic vaccination against hepatitis B virus.

Authors:  Claudia Dembek; Ulrike Protzer
Journal:  Med Microbiol Immunol       Date:  2014-12-19       Impact factor: 3.402

9.  Amphiregulin promotes the immunosuppressive activity of intrahepatic CD4+ regulatory T cells to impair CD8+ T-cell immunity against hepatitis B virus infection.

Authors:  Kai Dai; Ling Huang; Jing Chen; Lihua Yang; Zuojiong Gong
Journal:  Immunology       Date:  2015-03       Impact factor: 7.397

10.  The L60V variation in hepatitis B virus core protein elicits new epitope-specific cytotoxic T lymphocytes and enhances viral replication.

Authors:  Yu Zhang; Yulin Ren; Yan Wu; Bao Zhao; Lipeng Qiu; Xiaodong Li; Dongping Xu; Jun Liu; George F Gao; Songdong Meng
Journal:  J Virol       Date:  2013-05-15       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.